missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CX3CR1 Rat anti-Human, Brilliant Violet 421, Clone: 2A9-1, BD
Rat Monoclonal Antibody
Brand: BD Biosciences 565801
This item is not returnable.
View return policy
Description
The 2A9-1 monoclonal antibody specifically binds to human CX3CR1, which is also known as chemokine (C-C) receptor-like 1 (CCRL1), Beta chemokine receptor-like 1 (CMK-BRL-1), G protein-coupled receptor 13 (GPR13), or GPRV28 (V28). CX3CR1 is a seven transmembrane G protein coupled receptor that is expressed by NK cells, T cells, and monocytes. The cellular expression of CX3CR1 is correlated with high levels of intracellular perforin and granzyme B. CX3CR1 serves as a receptor for fractalkine (CX3CL1). Fractalkine is a transmembrane chemokine of the CX3C family that is expressed on activated endothelial cells, neurons, and astrocytes. Interaction of CX3CR1 with fractalkine initiates cellular adhesive and chemotactic responses.
The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.
Specifications
| CX3CR1 | |
| Monoclonal | |
| Brilliant Violet 421 | |
| Aqueous buffered solution containing BSA and ≤0.09% sodium azide. | |
| Human CX3CR1 Recombinant Protein | |
| 25 Tests | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
| Flow Cytometry | |
| 2A9-1 | |
| CCRL1; CMKBRL1; CMKDR1; GPR13; GPRV28; V28; Fractalkine Receptor | |
| Rat | |
| Affinity Purified | |
| RUO | |
| Human | |
| IgG2b κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only.
Spot an opportunity for improvement?Share a Content Correction